23 Lung Cancer Clinical Trials in Miami, TX (2026)

Q: Are there lung cancer clinical trials in Miami?

Yes, there are 23 lung cancer clinical trials currently recruiting in Miami, TX.

Q: How do I join a clinical trial in Miami?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Miami research site will contact you.

Q: Are clinical trials in Miami free?

Yes, clinical trial participation is always free. Study-related treatments, medical tests, and doctor visits are provided at no cost.

Recruiting Lung Cancer Studies in Miami

NCT07168993Recruiting

Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.

Evaluate FlowPath Lung Diagnostic Test of Sputum Samples to Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, \>6 to \<30 mm in Diameter, Determined by LDCT....

Miami, TX2,063 participantsbioAffinity Technologies Inc.

View Study Details

NCT05456841Recruiting

Empathic Communication Skills (ECS) Training

Research indicates that perceived stigma within medical encounters is prevalent and problematic for lung cancer patients' well-being and quality of cancer care. Promoting empathic communication appear...

Miami, TX1,232 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06561386Recruiting

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squa...

Miami, TX1,000 participantsBristol-Myers Squibb

View Study Details

NCT06077760Recruiting

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (...

Miami, TX868 participantsMerck Sharp & Dohme LLC

View Study Details

NCT05384626Recruiting

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of neladalkib (NVL-655), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activ...

Miami, TX840 participantsNuvalent Inc.

View Study Details

NCT06095583Recruiting

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination w...

Miami, TX756 participantsShanghai Junshi Bioscience Co., Ltd.

View Study Details

NCT06801834Recruiting

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

The goal of this clinical study is to learn more about the study drug sacituzumab govitecan (SG; Trodelvy®; GS-0132; IMMU 132), versus standard of care (SOC) in participants with previously treated ex...

Miami, TX695 participantsGilead Sciences

View Study Details

NCT06875310Recruiting

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemothera...

Miami, TX630 participantsMirati Therapeutics Inc.

View Study Details

NCT06203210Recruiting

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

This study was designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC)....

Miami, TX540 participantsDaiichi Sankyo

View Study Details

NCT05983432Recruiting

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors....

Miami, TX470 participantsSystImmune Inc.

View Study Details

NCT06765109Recruiting

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with...

Miami, TX450 participantsNuvalent Inc.

View Study Details

NCT06618287Recruiting

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors....

Miami, TX416 participantsBristol-Myers Squibb

View Study Details

NCT06780137Recruiting

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

Researchers are looking for new ways to treat people with extensive-stage small cell lung cancer (SCLC) that has relapsed or is refractory. Gocatamig is a new type of immunotherapy that uses a person'...

Miami, TX327 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06773910Recruiting

BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants. The main goals of...

Miami, TX250 participantsSCRI Development Innovations, LLC

View Study Details

NCT05882058Recruiting

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

This study is open to adults with small cell lung cancer and other neuroendocrine tumours. The study is in people with advanced cancer for whom previous treatment was not successful or no standard tre...

Miami, TX204 participantsBoehringer Ingelheim

View Study Details

NCT04614103Recruiting

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer...

Miami, TX170 participantsIovance Biotherapeutics, Inc.

View Study Details

NCT06463665Recruiting

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

This Phase 2, open-label, randomized study in non-small-cell lung cancer (NSCLC) is designed to evaluate the efficacy and safety of an intravenously delivered oncolytic vaccinia virus, Olvi-Vec, follo...

Miami, TX142 participantsGenelux Corporation

View Study Details

NCT06626243Recruiting

Analysis of RATS, VATS and Open Lung Resections After Neoadjuvant Chemo-immunotherapy in Patients Performed in Five Referred Centers

The study is a retrospective observational study. The study is designed to be multicentric and international and it will analyze medical records from selected patients diagnosed with locally advanced ...

Miami, TX140 participantsScientific Institute San Raffaele

View Study Details

NCT06667908Recruiting

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can i...

Miami, TX130 participantsJohnson & Johnson Enterprise Innovation Inc.

View Study Details

NCT05657873Recruiting

A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to see whether adding liver stereotactic ablative radiotherapy/L-SABR to standard drug therapy is better than standard drug therapy alone for people with metastatic non-sm...

Miami, TX68 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06741085Recruiting

A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain

The researchers are doing this study is to find out whether treating brain metastasis with SRS after 3 months of therapy with osimertinib is better than treating with osimertinib alone in people with ...

Miami, TX56 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT05877599Recruiting

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant solid tumors....

Miami, TX45 participantsAstraZeneca

View Study Details

NCT06902272Recruiting

ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer

The purpose of this study is to determine if a blood test called circulating tumor DNA (ctDNA) can be used to predict how well patients will respond to treatment and if there is any cancer left after ...

Miami, TX30 participantsUniversity of Miami

View Study Details

About Lung Cancer Clinical Trials in Miami

Lung cancer is the leading cause of cancer death worldwide, starting in the cells of the lungs. The two main types are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Treatments include surgery, chemotherapy, radiation, immunotherapy, and targeted drugs.

There are currently 23 lung cancer clinical trials recruiting participants in Miami, TX. These studies are seeking a combined 11,522 participants. Research is being sponsored by bioAffinity Technologies Inc., Memorial Sloan Kettering Cancer Center, Bristol-Myers Squibb and 15 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Lung Cancer Clinical Trials in Miami — FAQ

Are there lung cancer clinical trials in Miami?

Yes, there are 23 lung cancer clinical trials currently recruiting in Miami, TX. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Miami?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Miami research site will contact you about next steps.

Are clinical trials in Miami free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Miami studies also compensate for your time and travel.

What lung cancer treatments are being tested?

The 23 active trials in Miami are testing new therapies including novel drugs, biologics, and treatment approaches for lung cancer.

Data updated July 13, 2026 from ClinicalTrials.gov